Understanding the comprehensive genomic profile of a cancer patient's disease will enable better personalised healthcare
Roche and Foundation Medicine (FMI) have entered into a broad strategic collaboration to further advance FMI's market-leading position in molecular information and genomic analysis while providing Roche a unique opportunity to optimise the identification and development of novel treatment options for cancer patients.
FMI supports physicians by providing comprehensive molecular information to characterise a tumor that is being matched with approved targeted therapy options and novel treatments under development. Understanding the comprehensive genomic profile of a cancer patient's disease will enable better personalised healthcare solutions to optimise treatment outcomes for patients.
"We believe that putting molecular information at the center of cancer care will help transform the delivery of care for patients and speed the pace of drug discovery and development. The structure of our agreement with Roche also allows us to maintain the entrepreneurial spirit at Foundation Medicine and ensures that our business model, network of partnerships and objectives are not altered," said Mr Michael J Pellini, president and CEO, Foundation Medicine.
